---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-032513"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:37:03.218719+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances

## Summary
- Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).
- Cash $336.9M at Dec 31, 2023; plus $41.7M from Jan 2024 ATM; runway into late 2026.
- Four phase 1/2 trials ongoing; TNG908 clinical data expected 2024; first patient dosed for TNG348.
- FDA Orphan Drug Designation granted for TNG462 for soft tissue sarcomas.
- Appointed Chief Regulatory Officer, Chief Development Operations Officer, Chief Legal Officer.

## SEC filing metadata
- accession: 0000950170-24-032513
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/0000950170-24-032513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-032513
- JSON: https://secwatch.observer/filing/0000950170-24-032513.json
- Plain text: https://secwatch.observer/filing/0000950170-24-032513.txt

## Key facts
- Earnings Releases
  Tango Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 18, 2024, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/0000950170-24-032513-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.